利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

154 条记录 (耗时 0.031 秒)

    Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties
    6.
    发明授权
    Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties 有权

    公开(公告)号：US11534480B2

    公开(公告)日：2022-12-27

    申请号：US16414223

    申请日：2019-05-16

    申请人： Alkermes, Inc.

    发明人： Demetri T. Moustakas ,  Mark N. Namchuk ,  Heather C. Losey ,  Juan C. Alvarez

    IPC分类号： A61K38/20 ,  C07K14/54

    摘要： The invention provides compositions and methods for modulating the immunostimulatory properties and/or anti-inflammatory properties of IL-10. The present invention provides scIL-10 polypeptides of Formula 1. The polypeptides of the invention are optionally linked to a fusion partner. The polypeptides of Formula 1 are referred to herein as “scIL-10” polypeptides and comprise an amino acid sequence arrangement from N-terminus to C-terminus in accordance with Formula 1: (first monomer subunit)-LINKER-(second monomer subunit)   Formula 1 wherein the first monomer subunit, the second monomer subunit or both the first and second monomer subunits may be independently selected from: an unsubstituted IL-10 monomer subunit; or a substituted IL-10 monomer subunit comprising at least one amino acid substitution; and wherein LINKER is any amino acid linker of at least 1-100 amino acids in length.

    Fusion polypeptides comprising mucin-domain polypeptide linkers
    8.
    发明授权
    Fusion polypeptides comprising mucin-domain polypeptide linkers 有权

    公开(公告)号：US10183979B2

    公开(公告)日：2019-01-22

    申请号：US15044310

    申请日：2016-02-16

    申请人： Alkermes, Inc.

    发明人： Juan Alvarez ,  Leslie A. McSweeney

    IPC分类号： C07K14/435 ,  C07K14/55 ,  C07K14/47 ,  C07K14/545 ,  C07K14/54 ,  C07K14/715 ,  C07K14/50 ,  C07K14/705 ,  C07K14/71 ,  C07K14/575 ,  A61K38/00 ,  A61K39/00

    摘要： The invention provides fusion proteins having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker and wherein the bioactivity of the fusion protein of the invention is improved as compared to fusion of the first polypeptide fusion partner and the second polypeptide fusion partner in the absence of the mucin-domain polypeptide linker. Mucin-domain polypeptide linkers comprise a mucin domain that is rich in potential glycosylation sites, and has a high content of serine and/or threonine and proline, which can represent greater than 40% of the amino acids within the mucin domain and further comprise at least about 60% of its mass due to the glycans.